Amgen Dividends and Buybacks
Dividend criteria checks 5/6
Amgen is a dividend paying company with a current yield of 3.02% that is well covered by earnings. Next payment date is on 6th March, 2026 with an ex-dividend date of 13th February, 2026.
Key information
3.0%
Dividend yield
0.1%
Buyback Yield
| Total Shareholder Yield | 3.1% |
| Future Dividend Yield | 3.2% |
| Dividend Growth | 10.6% |
| Next dividend pay date | 06 Mar 26 |
| Ex dividend date | 13 Feb 26 |
| Dividend per share | n/a |
| Payout ratio | 72% |
Recent dividend and buyback updates
Recent updates
Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A "Buy"
Dec 10Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
Aug 13
Is Amgen (NASDAQ:AMGN) A Risky Investment?
Aug 01Amgen Inc.'s (NASDAQ:AMGN) Earnings Haven't Escaped The Attention Of Investors
Jun 20It's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge Pay Rise This Year
May 16Amgen: The Biotech That Knows How To Make Money
Apr 17Biosimilar Competition And TEPEZZA Approvals Will Define Future Path
Declining prices combined with biosimilar competition and loss of exclusivity threaten revenue growth and profit margins.Expanding Oncology Portfolio And International Launches Will Unlock Potential
Expansion in oncology and rare diseases, coupled with strategic pipeline innovations, promises substantial long-term revenue and earnings growth.Amgen: Excellent Buy And Hold For A Volatile Market
Mar 31Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 82% Above Its Share Price
Mar 29Amgen: Riding The MariTide Of Monthly Weight Loss
Mar 10Amgen Inc. (NASDAQ:AMGN) Not Flying Under The Radar
Mar 03Amgen Stock: Why I Still Rate It A 'Buy'
Feb 26Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Feb 06Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.38
Feb 01Amgen: Likely To Be Rangebound (Rating Downgrade)
Jan 20Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's
Jan 17Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold
Jan 05Amgen: MariTide Underwhelms, But There Are Ways To Win
Nov 26Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: AMGN's dividends per share have been stable in the past 10 years.
Growing Dividend: AMGN's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Amgen Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AMGN) | 3.0% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (AMGN) (up to 3 years) | 3.2% |
Notable Dividend: AMGN's dividend (3.02%) is higher than the bottom 25% of dividend payers in the US market (1.41%).
High Dividend: AMGN's dividend (3.02%) is low compared to the top 25% of dividend payers in the US market (4.41%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (72.1%), AMGN's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (47%), AMGN's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 00:22 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amgen Inc. is covered by 61 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Aaron Gal | Bernstein |